In the present investigation it was aimed to evaluate any possible pharmacokinetic interactions between Phenytoin and Rivaroxaban. Study was conducted in Male Wistar rats; animals were divided into three groups. Group 1 received Phenytoin alone, Group 2 received Rivaroxaban alone and Group 3 received Phenytoin and Rivaroxaban concomitantly. The treatment was given for 8 days and the blood samples were collected on day 1 and day 8. The samples were analyzed by HPLC. The results were showed no significant difference in the Pharmacokinetic parameters of Phenytoin in presence of Rivaroxaban. Whereas Rivaroxaban showed significant decrease in both Cmax and tmax in combination with Phenytoin. Phenytoin is a combined-gp inducer and strong CYP3A4 inducer therefore it may induce the metabolism of Rivaroxaban so it reduces the concentrations and increase the elimination rate. Based on the results obtained from pharmacokinetic study it was evident that the single dose of Rivaroxaban in combination with Phenytoin shows statistically significant interactions in its pharmacokinetic parameters.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.